Callahan Kathryn E, Lenoir Kristin M, Usoh Chinenye O, Williamson Jeff D, Brown LaShanda Y, Moses Adam W, Hinely Molly, Neuwirth Zeev, Pajewski Nicholas M
Section on Gerontology and Geriatric Medicine, Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC.
Center for Health Care Innovation, Wake Forest School of Medicine, Winston-Salem, NC.
Diabetes Spectr. 2022 Summer;35(3):344-350. doi: 10.2337/ds21-0068. Epub 2022 Mar 21.
Despite guidelines recommending less stringent glycemic goals for older adults with type 2 diabetes, overtreatment is prevalent. Pragmatic approaches for prioritizing patients for optimal prescribing are lacking. We describe glycemic control and medication patterns for older adults with type 2 diabetes in a contemporary cohort, exploring variability by frailty status.
This was a cross-sectional observational study based on electronic health record (EHR) data, within an accountable care organization (ACO) affiliated with an academic medical center/health system. Participants were ACO-enrolled adults with type 2 diabetes who were ≥65 years of age as of 1 November 2020. Frailty status was determined by an automated EHR-based frailty index (eFI). Diabetes management was described by the most recent A1C in the past 2 years and use of higher-risk medications (insulin and/or sulfonylurea).
Among 16,973 older adults with type 2 diabetes (mean age 75.2 years, 9,154 women [53.9%], 77.8% White), 9,134 (53.8%) and 6,218 (36.6%) were classified as pre-frail (0.10 < eFI ≤0.21) or frail (eFI >0.21), respectively. The median A1C level was 6.7% (50 mmol/mol) with an interquartile range of 6.2-7.5%, and 74.1 and 38.3% of patients had an A1C <7.5% (58 mmol/mol) and <6.5% (48 mmol/mol), respectively. Frailty status was not associated with level of glycemic control ( = 0.08). A majority of frail patients had an A1C <7.5% (58 mmol/mol) ( = 4,544, 73.1%), and among these patients, 1,755 (38.6%) were taking insulin and/or a sulfonylurea.
Treatment with insulin and/or a sulfonylurea to an A1C levels <7.5% is common in frail older adults. Tools such as the eFI may offer a scalable approach to targeting optimal prescribing interventions.
尽管指南建议对老年2型糖尿病患者采取较宽松的血糖控制目标,但过度治疗仍很普遍。目前缺乏将患者进行优先排序以实现最佳处方的实用方法。我们描述了当代队列中老年2型糖尿病患者的血糖控制情况和用药模式,并按虚弱状态探讨了其中的变异性。
这是一项基于电子健康记录(EHR)数据的横断面观察性研究,研究对象来自一个与学术医疗中心/卫生系统相关的责任医疗组织(ACO)。参与者为截至2020年11月1日年龄≥65岁且已加入ACO的2型糖尿病成年患者。虚弱状态通过基于EHR的自动虚弱指数(eFI)来确定。通过过去2年中最近的糖化血红蛋白(A1C)水平以及高风险药物(胰岛素和/或磺脲类药物)的使用情况来描述糖尿病管理情况。
在16973例老年2型糖尿病患者中(平均年龄75.2岁,9154名女性[53.9%],77.8%为白人),分别有9134例(53.8%)和6218例(36.6%)被归类为虚弱前期(0.10<eFI≤0.21)或虚弱(eFI>0.21)。A1C水平的中位数为6.7%(50 mmol/mol),四分位间距为6.2 - 7.5%;分别有74.1%和38.3%的患者A1C<7.5%(58 mmol/mol)和<6.5%(48 mmol/mol)。虚弱状态与血糖控制水平无关(P = 0.08)。大多数虚弱患者的A1C<7.5%(58 mmol/mol)(n = 4544,73.1%),在这些患者中,1755例(38.6%)正在使用胰岛素和/或磺脲类药物。
在虚弱的老年患者中,使用胰岛素和/或磺脲类药物将A1C水平控制在<7.5%的情况很常见。诸如eFI等工具可能为靶向最佳处方干预措施提供一种可扩展的方法。